Aim To evaluate the impact of pathological review by pathologist with genitourinary expertise (PGU) on treatment modality of localized prostate cancer, we analyzed Gleason grade (GG) migration and the final treatment decision in a cohort of patients designated for permanent prostate brachytherapy (PPB). Methods From February 2005 to July 2010, a total of 247 patients with localized prostate cancer diagnosed by local community hospitals were referred to our hospital for PPB monotheray. All pathologic slides of prostate biopsies were reviewed by a single PGU. Patients ultimately selected their treatment modality from our recommendations based on the review. Indication for PPB monotherapy was the NCCN classification of patients as good or intermediate risk. In addition, patient with Primary GG 4 was regarded as unadapted case. Results Six cases were reinterpreted as no cancer (2.4%). GG change occurred in 94 cases (38.1%) of which 77 (81.9%) were upgraded and 17 (18.1%) downgraded. Of the total 247 patients, 86 (34.8%) changed therapies and 30 (12.1%) did so based on the pathologic slide review. Conclusions Pathological review of biopsy specimens is mandatory for the determination of treatment modality especially in candidates for monotherapy of permanent prostate brachytherapy.
Introduction
Both cost and clinical benefits of a mandatory histopathological review of prostate biopsies by a central pathologist from patients diagnosed at outside institutions have been previously reported [1] [2] [3] . A second pathological review done by a central pathologist can result in a more accurate diagnosis, optimal treatment, and reduced cost. Although studies have recommended a mandatory second review of slides of prostate biopsies, approximately 50% of institutions have not followed the recommendation due to increased patient cost and pathologist work load. Our institution began routine reviewing of all pathologic slides of prostate needle biopsies from referring hospitals for optimal treatment decisions since permanent prostate brachytherapy (PPB) section was established.
PPB for localized prostate carcinoma is now widely used. In our institute, PPB has been done as monotherapy since we regarded the benefits of PPB as better QOL, such as shorter treatment periods, persistent of potency in early period, lower incidence of treatment complication. Although it is considered comparable to radical prostatectomy (RP) and external beam radiotherapy (EBRT), studies have reported outcomes of PPB monotherapy showed significantly different for Gleason score (GS) 4?3 and 3?4 adenocarcinoma [4, 5] . Based on those studies our criteria for patient eligibility for PPB monotherapy is NCCN classification of good or intermediate risk without GS 4?3. In this study, we compare reports of prostate biopsies from community hospitals with the review by a central PGU at our institution and evaluate the clinical impact on the treatment modality for patients diagnosed with local prostate cancer and referred for PPB monotherapy.
Materials and methods
When a patient was referred to our PPB institute for treatment of prostate cancer we requested all pathologic slides. Pathologic slides from 247 patients referred by outside hospitals were reviewed by one PGU (HY) at our institute. If major discrepancies were found, the treatment modality was reconsidered based on the PGU review.
Patient eligibility for PPB monotherapy was determined to be (1) NCCN prostate cancer classification of good or intermediate risk excluding GS 4?3, (2) prostate volume for transabdominal or transrectal ultrasonography less than 35 ml, (3) suitability of pelvic cavity shape, particularly the pubis, for PPB. This criteria conforms to the Japanese PPB guideline for safety administration of I-125 which recommended that the radioactivity in the prostate gland after PPB should be within 1,300 MBq based on Regulation of Japanese Government, which indicate that large prostate volume are contra-indication for PPB as a monotherapy.
Patients referred for PPB monotherapy underwent serum PSA testing, urinalysis, transabdominal ultrasonography, and a digital rectal examination on their first visit to our hospital. MRI findings and pathologic slides from the referring hospital were reviewed at that time. With an indication for PPB, patients underwent a pre-planning transrectal utrasonography. If prostate volume was greater than 35 ml, neoadjuvant hormonal therapy, an LHRH agonist, was used for approximately 3 months to decrease volume based on the results of previous articles [6] [7] [8] , and the prostate was reassessed by transrectal ultrasonography. When prostate volume was decreased but still over 35 ml after neoadjuvant hormonal therapy, we proposed another therapy, such as high-dose rate brachytherapy, external beam radiotherapy or radical prostatectomy with or without hormone therapy.
Patient characteristics, pathological reports from outside institutions, pathological review done at out institution, proposed treatment methods, and received treatment were recorded prospectively.
Results
Slides of 100 (40.5%) patients out of 247 showed pathologic discrepancies. Six patients were re-diagnosed as noncancerous disease, four (1.6%) as no malignancy and two (.08%) as atypical gland. GG discrepancy between original report and review occurred in 94 (38.1%) cases of which 77 (81.9%) were upgraded and 17 (18.1%) were downgraded (Table 1) . Table 2 shows absolute Gleason score change from outside pathologic reports and our review. Seventy-seven patients were upgraded by our review: 33 (42.9%) were initially diagnosed as GS 5 or less and 27 (35.1%) were GS 3?3. Twenty-five patients diagnosed as GS 3?4 or less than 6 were reinterpreted as GS 4?3 or more than 8 and excluded as candidates for PPB.
Seventeen patients initially determined to be ineligible for PPB by the primary pathologic diagnosis had their GS downgraded: 4 were reinterpreted from GS 4?3 or more than 8 to GS 3?4 or 3?3 and became eligible for PPB.
Reinterpretations between GS 3?4 and 4?3 occurred in 10 patients: 8 were changed from 3?4 to 4?3 and 2 from 4?3 to 3?4.
Based on clinical assessments including the pathologic review, 161 patients received PPB and 86 changed to other treatment modalities (Fig. 1) . Major reasons for change therapy of those patients were unsuitable pelvic shapes, prostate volume [35 ml after neoadjuvant hormone therapy, patient performance status was too low, etc. Of the 161 who underwent PPB, 5 (3.1%) were regarded as eligible on the second review. Twenty-five (29.1%) patients of the 86 who chose another treatment changed after the second review (Fig. 2) . 
Discussion
Studies have reported on the cost and clinical benefits of a pathologic review for localized prostate cancer [1] [2] [3] . Epstein et al. [1] reported that the cost of reviewing 535 preoperative needle biopsies was $44,883 and the cost of avoiding prostatectomies in 6 patients was $85,686. Wurzer et al. [3] described the cost-effectiveness and improvement in clinical treatment with a pathologic review of prostate biopsies in 1998. This problem has occurred not only with urologic cancer but in other body sites [9] [10] [11] [12] [13] [14] . Although these studies recommend a mandatory second review of pathologic slides, and the Association of Directors of Anatomic and Surgical Pathology (ADASP) recommend that diagnoses listed in final reports be compared with those made at referring institutions [15] , only half of institutions have practiced it when patients were referred [11] . Brimo et al. [2] described the main reasons for not following the recommendation were problems of delayed treatment, increased patient cost, increased pathologist work load, and institutional administrative concerns over budget constraints. The rate of diagnostic discrepancies in studies of all body sites is less than 10%, but the rate in studies of prostate cancer is significantly higher. One of the major reasons for the higher rate of difference in prostate diagnosis is considered to be the segmentation of the Gleason grading system. Studies of discrepancies in prostate specimens describe that the rate of Gleason Grade discordance was significantly higher (range 14.2-57%) [1, 2, [16] [17] [18] , but the rate of histology discordance between malignant or not (range 1.2-3.2%) [1, 2, 16] was almost the same as other origins (range 1.4-2.6%) [9, 14, 19] . Jara-Lazaro et al. [16] reported that of their 323 pathologic reviews, discordant diagnoses were 183 (57%), but 132 were Gleason Grade discordance and only 24 (7.4%) were reinterpreted as malignant, benign, or HGPIN. Our study showed discrepancies of pathologic diagnosis in 100 patients (40.5%) and of those only 6 (2.4%) were changed from malignant to non-malignant disease. Although Gleason grade discrepancy often occurs because of its segmentalisation, the Gleason grade is one of the most important factors for predicting cancer outcome. Partin et al. [20] [21] [22] first published the nomogram for localized prostate cancer using PSA, clinical stage, and Gleason score in 1993, updated it in 1997, and again in 2001. Currently, many nomograms use the Gleason score and urologists decide treatment modalities with them, so an accurate diagnosis is essential.
Brachytherapy is recommended as one useful modality for the patient with localized prostate cancer. Although the clinical outcome of brachytherapy is similar to other modalities such as prostatectomy or EBRT, several studies have revealed that primary GG 4 is an important factor for biochemical recurrence (BCR)-free survival for PPB in the last decade. Uesugi et al. [5] reported that primary GG 4 had a worse BCR than primary Grade 3 in 414 patients with localized prostate cancer who underwent PPB. And monotherapy of low dose brachytherapy was recommended only for low or intermediate risk patients [23] . In the current study, the pathologic review had an impact on the selection of treatment modality in over 10% of the candidates for PPB. Accurate pathologic diagnosis of specimens from prostate needle biopsies is necessary, especially when PPB is selected.
The current study has several limitations. First, it does not evaluate cost benefits. This is due to the Japanese medical insurance system not covering the cost of a second review. Pathologists must therefore volunteer the service, rendering the cost inestimable. Secondly is the selections bias of the cohort in this study. Patients were referred to our institution for brachytherapy and many were selected based on our eligibility criteria by outside hospitals. Finally, the GS of this cohort has a tendency to be lower and, thusly, after pathological review, the number of upgrades appears larger than downgrades. 
Conclusions
In this study, about 40% of patients diagnosed with localized prostate cancer in outside hospitals and referred to our institute were re-diagnosed after a review of pathological slides of prostate needle biopsies by central PGU. In addition, 10% of patients were changed to other therapies form PPB monotherapy by only pathological review in this series. Although this high rate accounted for PPB monotherapy criteria limitation, it is clear that an accurate pathological diagnosis is one of the most important factors for decision of cancer treatment modality. This study shows pathological review for biopsy specimen is mandatory for determination of treatment modality.
